Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 8/20 | 0.39 |
| ▸ | ACACA | Q13085 | 8/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | PDE5A | O76074 | 2/20 | 0.31 |
| ▸ | PDE1A | P54750 | 2/20 | 0.31 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.31 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.31 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2350066 | 0.88 | ACACB (0.35) | ACACBACACAALDH1A1KMT2ABRD4 | |
| SCHEMBL2353457 | 0.85 | ACACB (0.52) | ACACBACACAPGR | |
| SCHEMBL2353965 | 0.82 | ACACB (0.40) | ACACBACACAALDH1A1 | |
| SCHEMBL811937 | 0.80 | MEN1 (0.34) | ACACBACACAALDH1A1KMT2A | |
| SCHEMBL811962 | 0.79 | ACACB (0.55) | ACACBACACAKMT2APDE5APDE1A | |
| SCHEMBL812270 | 0.78 | NPC1 (0.32) | ACACBACACAALDH1A1KMT2A | |
| SCHEMBL812271 | 0.77 | ACACB (0.37) | ACACBACACAALDH1A1BRD4PGR | |
| SCHEMBL15472969 | 0.72 | ACACB (0.56) | ACACBACACA | |
| SCHEMBL2348721 | 0.70 | ACACB (0.55) | ACACBACACA | |
| SCHEMBL14017525 | 0.70 | ACACB (0.53) | ACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8058210-B2 | Arylphenyl-substituted cyclic keto-enols | BAYER CROPSCIENCE AG (DE) | 2011-11-15 | — | — | US | disclosed |
| US-7718706-B2 | Arylphenyl-substituted cyclic keto-enols | BAYER AKTIENGESELLSCHAFT (DE) | 2010-05-18 | — | — | US | disclosed |
| US-7718706-B2 | Arylphenyl-substituted cyclic keto-enols | BAYER AKTIENGESELLSCHAFT (DE) | 2010-05-18 | — | — | US | disclosed |
| US-20100087320-A1 | ARYLPHENYL-SUBSTITUTED CYCLIC KETO-ENOLS | LIEB FOLKER | 2010-04-08 | — | — | US | disclosed |
| US-20100087320-A1 | ARYLPHENYL-SUBSTITUTED CYCLIC KETO-ENOLS | LIEB FOLKER | 2010-04-08 | — | — | US | disclosed |
| US-20080081807-A1 | Arylphenyl-substituted cyclic keto-enols | LIEB FOLKER | 2008-04-03 | — | — | US | disclosed |
| US-20080081807-A1 | Arylphenyl-substituted cyclic keto-enols | LIEB FOLKER | 2008-04-03 | — | — | US | disclosed |
| US-7288676-B2 | Arylphenyl-substituted cyclic ketoenols | BAYER CROPSCIENCE AG (DE) | 2007-10-30 | — | — | US | disclosed |
| US-7288676-B2 | Arylphenyl-substituted cyclic ketoenols | BAYER CROPSCIENCE AG (DE) | 2007-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081807-A1 | Arylphenyl-substituted cyclic keto-enols | KCNE1, DDT, KCNQ3 | ACACB 971/4885ACACA 1353/4885ALDH1A1 2569/4885 |
| US-20100087320-A1 | ARYLPHENYL-SUBSTITUTED CYCLIC KETO-ENOLS | KCNE1, DDT, KCNQ3 | ACACB 971/4885ACACA 1353/4885ALDH1A1 2569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.